In-Vitro, In-Vivo and Life Science - Clinical Research Informer

Innovative assays for neurodegeneration drug discovery programs

Drug Discovery World

NOVEMBER 15, 2022

In this on-demand webinar, presented by Dr Elise Malavasi, Principal Scientist at Concept Life Sciences, we use multiple sclerosis as a case-study of a neurodegenerative disease, so you can: Understand the key processes in neurodegeneration. Discover how in vitro assays can be used to model in vivo neurodegeneration.

In-Vitro

In-Vitro In-Vivo Drugs Life Science

Webinar: Innovative assays for neurodegeneration drug discovery

Drug Discovery World

NOVEMBER 15, 2022

Discover how in vitro assays can be used to model in vivo neurodegeneration. Discover how in vitro assays can be used to model in vivo neurodegeneration. Brought to you by DDW and Malvern Panalytical, the webinar is presented by Dr Elise Malavasi, Principal Scientist at Concept Life Sciences.

In-Vitro

In-Vitro Drugs In-Vivo Life Science

How Much Do You Know About in silico Trials?

XTalks

APRIL 14, 2022

Conventional in vitro and in vivo studies are used in the drug development pipeline. However, could there be another way for developing biomedical products using in silico technology? This involves the use of an individualized computer simulation for medical device or drug development. Want to learn more?

Trials

Trials In-Vivo In-Vitro Clinical Trials

€2m raised in seed funding to develop novel therapies for Cystic Fibrosis

Drug Discovery World

JUNE 19, 2023

This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership announced in May 2022 to finance, support and grow Europe’s most innovative life science startups. Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate.

Development

Development Life Science In-Vivo In-Vitro

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The Pharma Data

JANUARY 6, 2021

SK Chemicals has shared their expertise in these diseases and validated the predicted targets and compounds through in vitro and in vivo studies. SK Chemicals is a leading company in the fields of chemistry and life science. SK Chemicals is a leading company in the fields of chemistry and life science.

FDA Approval

FDA Approval Life Science Drugs In-Vivo

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers.

Research

Research In-Vitro In-Vivo Development

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science

Life Science Antibody In-Vivo In-Vitro

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials

Clinical Trials Clinical Trials Trials Antibody

What an innovation centre means for 3D biology

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades.

Drugs

Drugs In-Vivo In-Vitro Scientist

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations. A solution could be at hand with Overland Pharmaceuticals. Overland aims to build a leading, fully integrated biopharma company by leveraging global networks and formative R&D partnerships.

In-Vivo

In-Vivo In-Vitro Antibody Development

Reflecting on ELRIG’s Drug Discovery 2022

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery.

Drugs

Drugs In-Vivo In-Vitro Biobanking

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

APRIL 3, 2023

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. What advice would you offer to similar start-ups?    AT: Integral to Aptamer Group’s offering is an in-depth understanding of molecular science.

Antibody

Antibody Gene Therapy Gene In-Vitro

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA

RNA Protein DNA In-Vivo

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

A life-changing moment came for Dr. Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. The journey first starts with the decision to make the switch. Key Moments.

Scientist

Scientist In-Vitro Research Life Science

Clinical Research Informer

Innovative assays for neurodegeneration drug discovery programs

Webinar: Innovative assays for neurodegeneration drug discovery

Trending Sources

How Much Do You Know About in silico Trials?

€2m raised in seed funding to develop novel therapies for Cystic Fibrosis

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The evolution of assays for immuno-oncology research

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

What an innovation centre means for 3D biology

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Reflecting on ELRIG’s Drug Discovery 2022

Turning science into business: An optimised alternative to antibodies

What the Glycome Can Tell Us About Persistent HIV Infection

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

Stay Connected